市场调查报告书
商品编码
1411270
胱抑素 C 测定市场 - 依产品(试剂盒、试剂、分析仪)、依样本种类(血液、尿液)、依方法(ELISA、PETIA、PENIA、CLIA、免疫萤光测定)、按应用、最终用途与预测,2024-2032 年Cystatin C Assay Market - By Product (Kits, Reagents, Analyzers), By Sample Type (Blood, Urine), By Method (ELISA, PETIA, PENIA, CLIA, Immunofluorescence Assay), By Application, End use & Forecast, 2024-2032 |
预计从 2024 年到 2032 年,胱抑素 C 检测行业规模将以超过 7.7% 的CAGR扩大。全球慢性肾臟病(CKD) 患病率不断上升,加上人口老龄化,正在推动对准确和早期诊断工具(例如胱抑素)的需求C 测定。
最近,人们越来越认识到肌酸酐等传统生物标记在检测早期肾功能障碍方面的局限性。技术的不断进步导致了更灵敏和更特异的检测方法的开发。例如,2022 年 8 月,瑞士医疗科技公司 Bloom Diagnostics 推出了 Bloom Kidney Test,旨在量化全血中的胱抑素 C。对预防性医疗保健的日益重视以及医疗保健系统中创新诊断解决方案的整合也将推动市场扩张。
胱抑素 C 检测市场分为产品、样品类型、方法、应用、最终用途和地区。
就产品而言,由于慢性肾臟病患病率不断上升,对可靠诊断工具的需求不断增加,预计2024年至2032年试剂领域的产业价值将以7.7%的CAGR成长。试剂技术的不断进步正在提高准确性和灵敏度。此外,人们日益认识到传统生物标誌物的限制将促进该领域的成长。
胱抑素 C 检测市场的尿液样本部分预计在 2024 年至 2032 年间复合CAGR为7.5%。这一增长可归因于对精确肾功能评估的需求增加以及人们对基于尿液的胱抑素C 检测优势的认知不断提高。此外,肾臟疾病发生率的上升将进一步推动尿液采样的采用。
从地区来看,2024 年至 2032 年,欧洲胱抑素 C 检测行业规模预计将以 7.8% 的CAGR扩大。这一增长可归因于慢性肾病病例激增、人口迅速老化以及先进诊断技术的日益采用。此外,对医疗基础设施发展和预防医学的高度重视将推动区域市场的扩张。
Cystatin C assay industry size is projected to expand at over 7.7% CAGR from 2024 to 2032. The rising prevalence of chronic kidney diseases (CKDs) globally, coupled with the aging population is driving the demand for accurate and early diagnostic tools, such as cystatin C assays.
Of late, there has been growing awareness about the limitations of traditional biomarkers like creatinine in detecting early-stage kidney dysfunctions. The increasing technological advancements are leading to the development of more sensitive and specific assays. For instance, in August 2022, Bloom Diagnostics, a Swiss MedTech company, launched Bloom Kidney Test, designed for quantifying cystatin C in whole blood. The surging emphasis on preventive healthcare and the integration of innovative diagnostic solutions in healthcare systems will also fuel the market expansion.
The cystatin C assay market is segregated into product, sample type, method, application, end-use, and region.
In terms of product, the industry value from the reagents segment is estimated to rise at 7.7% CAGR from 2024 to 2032, owing to the increasing demand for reliable diagnostic tools due to the rising prevalence of chronic kidney diseases. The ongoing advancements in reagent technology is leading to enhanced accuracy and sensitivity. Additionally, the growing awareness of the limitations of traditional biomarkers will boost the segment growth.
The urine sample segment of the cystatin C assay market is estimated to depict 7.5% CAGR between 2024 and 2032. The growth can be attributed to the heightened demand for precise kidney function assessment and the increasing awareness of the advantages of urine-based cystatin C testing. Moreover, the higher incidences of renal disorders will further drive the adoption of urine sampling.
Regionally, the Europe cystatin C assay industry size is projected to expand at 7.8% CAGR from 2024 to 2032. The growth can be attributed to the surge in chronic kidney disease cases, rapidly aging population, and the increasing adoption of advanced diagnostic technologies. Additionally, the high emphasis on healthcare infrastructure development and preventive medicine will drive the regional market expansion.